Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone 2014-2015 Formulations
NCT02258334Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated), Fluzone Intradermal, trivalent inactivated influenza vaccine high-dose in influenza, sponsored by Sanofi. Started Oct 2014; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)Fluzone Intradermaltrivalent inactivated influenza vaccine high-dose
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02258334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258334.